Linda Shore-Lesserson, MD

• Professor of Anesthesiology
• Chief, Cardiothoracic Anesthesiology
• Montefiore Medical Center
• Bronx, New York

Atropine pretreatment may be given to block the muscarinic effects of neostigmine blood pressure medication verapamil cheap 240 mg calan with mastercard. Though specific antivenom serum is the primary treatment hypertension drug proven calan 80 mg, neostigmine + atropine prevent respiratory paralysis blood pressure low purchase calan 80 mg overnight delivery. It penetrates blood-brain barrier and antagonites both central and peripheral actions hypertension icd 9 code purchase discount calan online. However blood pressure medication exforge best 240 mg calan, physostigmine oflen itself induces hypotcnsion, arrhythmias and undesirable central efTects. Overdose symptoms and coma produced by these drug~ are partly antagoni7cd by phys0s1 inc. Various measures to augment cholinergic transmission in the brai n have been tried. They are· Irritation of eye, lacrimation, salivation, weatin g, copious tracheo-bronchial secretions, miosis, blurring of vision, bronchospasm, breathlessness, colic, involuntary defecation and urination. Tennination of further ex posure to the poison- fresh air, wash the skin and mucous membranes with soap and water, gastric la vage accordi ng to need. Specific antidotes- (a) Atropine It is highl y effective in counteracting the muscarini c symptoms, but higher doses are required lo antagonize the central e! Its oxime end reacts with the phosphorus atom attached to the esteratic site: the oxime-phosphonate so formed di ffuscs away leaving the reacti vated ChE. Pra lidoxime is ineffective as an antidote to carbamate anti-ChEs (physostigmi ne, neostigmi ne, carbaryl, propox ur) in which case the anionic site of the enzyme is not free to provide attachment to it. It is rather contraindicated in carbamatc poisoning, because not only it does not reactivate carbamylated enzyme. The role of oximes in o rganophosphate poisoning is only adj unctive to that of atropine, which remains the primary ant idote. In the second phase, spasticity and u1> per motor neurone paralysis gradually supcn enes. The mechanism of this toxicity is not luiown, but it is not due to inhibition of ChE; there is no specific treatment. Prominent effects are seen in organs which normally receive strong parasympathetic tone. Higher the ex1st1ng vaga l tone- more marked is the tachycard ia (max imum in young adults, less in children and e lde rl y). This is suggested by the finding that selective M 1 antagoni st pirenzepine is eq ui pote nt to atropine in causing bradycardia. Moreover, atropine substitutes which do not cross bloodbrain barrier also produce initial bradycardia. Atropine abbreviates re fractory period of A-V node and faci litates A-V conduction, especially if it has been depressed by h igh vagal tone. Tects are not appreciable at low doses which produce only peripheral effects because of restricted e ntry into the brain. The site of th is action is not c lear- probably there is a cholinergic link in the vestibular pathway, or it may be exerted at the co rtical level. Majority of the cen tral actions ore due to blockade of muscarinic receptors in Lhe brain, but some actions may have a different basis. Topical instillation of atropine causes myd riasis, abol it io n of light reflex and cycloplegia lasting 7- 10 days. Smooth muscles All v isceral smooth muscles th at receive parasy mpath etic motor innervation are relaxed by atropine (M. Tone and amplitude of contractions of stomach and intestine are reduced; the passage of c hyme is slowed-constipation may occur, spasm may be relieved. Atropine has relaxant action on ureter and urinary bladder; urinary retention can occur in older males wi th prostatic hypertrophy. However, this relaxant action can be benefi cial for increasing bladder c apacity and controll ing detrusor hyperreflexia in neu rogen ic bladder/enuresis. Long ciliary nerve (Sympathetic) Sphincter pupillae Iris Dilator pupillae Short ciliary nerve / (Paras m Cthetic:tsJ Ciilary ganglion Contraction of dilator pupillae [u, Adrenerg,c agonists] Relaxation of sphincter pupillae Antimuscanmc] [Ganglion blocker 5. Atropine decreases secretion of acid, pepsin and mucus in the stomach, but the primary action is on volume of secretion so that pH of gastric contents may not be e levated unless dilute d by food. Relatively hig he r doses a re needed and a tropine is less efficacious than H2 blockers in reduc ing acid secretion. Enhanced motility due to injected c hol inergic drugs is more completely antagonised than that due to vagal stimulation, because intramural neurones which arc activated by vagus utilize a number of noncho linergic transmillers as well. It is due to both inhibition of sweating as well as s timulation of temperature regulatin g centre in the hypothalamus. This is due 10 blockade of release inhibitory muscarmic autoreccptors present on these nerve 1em1inals. The above differences probably renect the relative dependence of the function on cholincrgic tone vis a,·i s other innuences. The pattern of relative ac1i, ity is nearly the same for other atropine s ubs titutes except pire11=epi11e which inhibits gastric secretion al doses 1ha1 have little effect on other secretions. This is probably because atropine equally blocks M, M, and M, receptors "hcrcas piren7epinc is a selective M, antagonist. Most of these differ on ly marginally from the natural alkaloids, but some appear promising. Atropine more effectively blocks responses to exogenously administered cholinergic drugs than those to parasympathetic nerve activity. Quaternary compounds these drugs have certain common features· Incomplete oral absorption (I 0-30%). Some degree of ganglion ic blockade may occur at clinical doses producing postural hypotension a nd impotence as additional side effects. Hyoscine this natural antichol inergic alkaloid differs from atropine in many respects; these differences are presented in Table 8. About 50% of atropine is metabo lized in liver and rest is excreted unchanged in urine. Hyoscine is more completely metabol ized and has heller blood-brain barrier penetration. Another desirable feature is that in contrast to atropine, it does not depress mucociliary clearance by bronchial epithelium. It has a gradual onset and late peak (at 40-60 min) of bronchodilator e ffect in comparison to inhaled ympatho mimetics. Thus, it i more suitable for regular prophylactic use rather than for rapid symptomatic relief during an attack. Transient local s ide effects like dryness of mouth, scratching sensati on in trachea, cough, bad taste and nervousness are reported in 20- 30% patients, but systemic effec ts are rare because of poor absorption from the lungs and g. T 20 µg and 40 µg,pufT metered dose mhaler, 2 puffs 3-4 times daily: 250 µg/ml respirator soln. It has some gangl ion blocking activity as we ll and is claimed to reduce gastric secretion at doses which produce only mild side effects. Oxyphenonium 5- 10 mg (children 3- 5 mg) oral; si milar to propantheline, recommended for peptic ulcer and gastrointestinal hypermotility. Cimetropium bromide A qua the rn a ry ammonium anticholinergic-antispasmodic drug, espec ially promo ted for! Tiotropium bromide A newer congener of ipratropium bromide which binds very ti ghtly to bronchial M / M 3 muscari nic receptors producing long lasting bronchodi latation. It exerts antispasmodic action at doses whic h produce few atropinic s ide e ffects. However, infants have exhibited atropi nic toxicity symptoms a nd it is not recomme nded below 6 months of age. Because of vasicoselective action, it is used for detrusor instab ility result ing in urinary frequency and urge incontine nce. Beneficial effects have been demonstrated in post-prostatectomy vas ical spasm, neurogenic bladder, spina bifida and nocturnal enuresis. Anticholinergic side effects are common after oral dosing, but intravesical instillation increases bladder capacity with few side effects. Tolterodine: Th is relatively M3 selective muscarinic antagonist has preferential action on urinary bladder; less likely to cause dryness of mouth and other anticholinergic side effects. Flavoxate It has properties si milar to oxy butynin a nd is ind icated in urinary frequency, urgency and dysuria associated with lower urinary tract infection. Darifenacin Another re latively M 3 selective antimuscarinic with preferential action on bladder muscles; indicated in urinary incontinence, urgency and frequency. The bio logical t½ is 13- 19 ho urs and the extended release tablet works for 24 hours. Oxybutynin this anti muscarinic has hi gh affini ty for receptors in urinary bladde r and sali vary g la nds alongw ith addi ti o nal smooth muscle relaxant and local anaesthetic prope rti es. Solifenacin It is similar to dari fenacin; no cli nically significant di fference between the two has bee n obse rved in clinical trials on patients with overacti ve bladder. As antisecretory Mydriatics A tropi ne is a pote nt mydriatic but its s low a nd lo ng -last ing action is undesirab le fo r refracti on testing. Though the pupil dilates in 30-40 min, cycloplegia takes I 3 hours, and the subject is visually handicapped fo r about a week. Instilled in the eye, it acts in 45 60 mi n, mydriasis lasts 1-3 days while accommodati on recovers in 1- 2 days. Cyclopentolate It is potent and rap idl y acting; mydri as is a nd cyc lo plegia occur in 30-60 min and last about a day. It is prefe rred fo r cycloplegic re fracti on, bu t chi ldren may show transie nt behavioural abnormali ties due to absorpt ion of the drug after passage into the nasolacrima l duct. Intestinal and renal colic, abdominal cra mps: symptomatic relief is afforded if there is no mechanical obstruction. Atrop ine is less effective in biliary colic and is not able to completely counte ract bi liary spasm due to opiates (nitrates are more effective). Nervous, functional and drug induced diarrhoea may be controlled to some extent, but anticholinergics are nol useful in infective diarrhoea. Tropicamide It has the qui ckest (20-40 min) and briefest (3-6 hours) action, but is a re latively unreliable cycloplegic. I lowever, it is satisfactory for refraction testing in adul ts and as a short acting mydriat ic for fundoscopy. Yasicose lective M 3 a ntimuscarinics like oxybutyn in, tolterodi ne, flavoxate and darifenacin have demo nstrated good efficacy. They may also increase bladder capacity, but dry mouth and other anticho1inergic effects are dose limiting. Tropicamide having briefer action has now largely replaced homatropine for this purpose. Phenylephrine is often combined with tropicamide for faster a nd stronger mydriatic action. These drugs do not cause sufficient cycloplegia in children: more potent agents like atropine or hyoscine have to be used. Atropine ointment (1%) applied 24 hours and 2 hours before is often preferred for children below S years. To facili tate fundoscopy only mydriasis is needed; a short acting antimuscarinic may be used, but phcnylcphrine is preferred, especiall y in th e elderly, fo r fea r of precip itat in g or aggravati ng g laucoma. Orally administered atropinic drugs are bronchodilators, but less effective than adrenergic drugs; not clinically used. They dry up secretion in the respiratory tract, may lead to its inspissation and plugging of bronchioles resulting in alveolar collapse and predis position to infect io n. Given by aerosol, it neither decreases respiratory secretions nor impairs mucociliary c learance, and there are few systemic side effects. Its time course of action makes it more suitable for regular prophylactic use rather than for control of acute anacks. As cardiac vagolytic Atropine is useful in counteracting sinus brad ycardia and partial heart block in selected patients w here increased vagal tone is responsible. Exc itement, psychotic behaviour, ataxia, del irium, dreadfu l visua l hallucinations. Hypotension, weak and rapid pulse, cardiovasc ular collapse with respiratory depression. It is particularly valuable in highly susceptible ind ividuals and for vigorous motions. A transdermal preparation appl ied behind the pinna 4 hours before journey has been shown to protect for 3 days. Side effects with low oral doses and transdem,al medication are few, but dry mouth and sedation can occur: driving is risky. Other genera l meas ures (ma intenance of b lood vo lume, assisted respiration, diazepam to control convuls ions) should be taken as appropri ate. Contraindications Atropinic drugs are absolutely contraindicated in indi viduals with a narrow iridocomeal angle- may p recipitate acute congestive g lauco ma. H owever, marked ri se in intraocu lar tension is rare in patients with w ide angle glaucoma. Caution is advocated in elderly males with prostatic hypertrophy- urinary retention can occur. To antagonise muscarinic effects of drugs and poisons Atropine is the specific antidote for anti Ch£ and ea rly mushroom poisoni ng (see Ch. Atropine or g lycopyrro late is a lso given to block muscarinic actions of neostigmine used for myasthenia gravis, decurari zatio n or cobra e nvenomation. Dry, flushed and hot skin (espec ially over face and neck), fever, difficulty in micturition, Interactions I.

Stages and forms of the parasite at which different types of antimalarial drugs act are indicated blood pressure high bottom number discount 240 mg calan fast delivery. A combined formulat ion ofato prehypertension uk purchase calan 240 mg otc,aquone (250 rng) + proguanii (100 mg) is commonly used as a prophylactic by Americans and other western travellers visiting malaria endemic areas blood pressure 9060 cheap calan 80 mg overnight delivery. In India blood pressure template purchase cheap calan, use of mefloquine fo r prophylax is no t allowed among residents connexin 43 arrhythmia purchase calan 120 mg free shipping, but may be used by travelle rs fo r long term (6 weeks to I year) prophylax is. Suppressive prophylaxis the schizontocides which suppress the erythrocytic phase and thu s attack of malarial fever can be used as prophylactics. Though the exoerythrocytic phase in case of vivax and other relapsing malarias continues, clinical di sease does not appea r. Erythrocytic Phase Activity + + + Onset Fast Int Int Int Slow Duration Long Long Short Short Long Hypnozoite Gametes Resist- ance Slow Minor Minor Rapid Rapid Toxicity grading + ++ +++ ± + ++ +± + + + + Chloroquine Mefloquine Quinine Proguanil Pyrimethamine Primaquine Sulfonamides Tetracyclines Clindamycin Artemisinin Lumefantrine + + + + ± + + + + 5. C hemo proph ylax is of ma laria s hou ld be li mited to short-term use in s pecia l risk groups, such as - nonimmune travellers, nonimmune persons li ving in endemic areas for fixed periods (army units, labour forces), infants, children and pregnant women (fa lciparum malaria has seri ous consequences in the pregnant). Clinical cure The erythrocyti c sch izontocides are used to terminate an episode of malarial feve r. The faster acting drugs are preferred, particularly in falciparum malaria where delay in treatment may result in death even if the parasites arc cleared from blood by the drug. The cxoerythrocytic phase (hypnozoites) of vivar and ovate persists which can cause relapses subsequently w ithout reinfection. Thus, the crythrocY1ic schizontocides are rad ical curatives for falciparum, but not for vivax or ovate malaria. However, recrudescences occur in falciparum infection if the blood is not total ly cleared of the parasites by the drug. The drugs and reg imens used for uncomplicated falci pa rum and vivax ma lari a are given in the box (p. Relapses of vivax/ovale ma laria are treated in the same way as the primary attack because the parasite remains sensitive to the d rug. Chloroquine 600 mg (1O mg/kg) followed by 300 mg (5 mg/kg) after 8 hours and then for next 2 days (total 25 mg/kg over 3 days) + Primaquine 15 mg (0. Antirelapse treatment with 14-day course of primaquine may be started concurrently. Falciparum malaria during pregnancy An attack of falciparu m malaria during pregnancy has seri ous implications both for the mother as well as the foetus. Vivax malaria during pregnancy It can be treated with chloroquine as in non-pregnant, but ra dical c ure with primaquine sho u ld be postponed till after delivery. A radical cura tive is needed in re lapsing ma laria, whi le in falc iparum malaria adequate treatme nt of c lin ical attack leaves no paras ite in the body (there is no secondary exoerythrocytic tissue phase). Gametocidal action is of no benefit to the pa tient bei ng treated, but wi ll reduce transmission to mosq uito. Gametes cxposesd to progua ni l may fai l to carry on the li fe cyle normally in the mosquito. T his should be given even w hen an artemisinin is used for clinical cure because a1temisinins do not kill all the gametes. Primaquine used for radical cure of vivax malaria e lim inates Pvivax gametes as well. Because P falciparum produces the more severe forms of malaria with considerable mortal ity, emergence of s uch stra ins is the biggest threat to the antima laria programmes, and is the focus of attention for c urrent research e fforts. Chloroquine-res istance among P falciparum is now w idespread in Indi a, and no entirely sensitive areas can be indentified. Howeve r, it has no effect on primary a nd secondary hepatic stages of the parasite-does not prevent re lapses in vivax and ovale ma laria. Plasmodia derive nutritio n by digesting hae moglo bin in th e ir acidic vacuo les. By accumulating in the acidic vecuoles of the paras ite and because of its weakly basic nature, it raises the vacuolar pH and thereby interferes with degradation of haemoglobin by parasi tic lysosomes. Othe r related anti malaria ls like quinine, mefloquine, lumefantrine, pyronaridine appear to act in an analogous manner. Chloroq uine-resistance a mong P vivax has been slow in developing, but P falciparum has acquired significant res istance, and resistant stra ins have become prevalent in India (especially the east and north east), South East Asia, China, Africa and South America. Some of these have Chloroqu ine-res istance among P vivax was first reported fro m Papua New Gu inea in 1989. It manifests as recrudescence within 1- 3 weeks of treating v ivax malaria with sta ndard dose of chloroqui ne. Preparations and administration Chloroquine phosphate: (250 mg = 150 mg base) b itter, tablet should no t be chewed. Other actions Chloroquine is active agai nst Entamoeba histolytica a nd Giardia lamblia as well. It has high affinity for me la nin and nuclear chromatin: gets tightl y bound to these tissue constituents and is concentrated in liver, spleen, kidney, lungs (several hu ndred- fold), skin, leucocytes and some other tissues. Its selective accumulation in retina is responsible for the ocular toxicity seen with prolonged use. Because of tight tissue bi nding, small amounts persist in the body with a terminal t½ o f 1- 2 months. Corneal deposits may also occur and affect vision, but arc reversible on discontinuation. A sin gle dose (15 mg/kg) controls fever and elim inates circulating parasites in infectio ns ca used by P. It is high ly plasma protein bou nd and concentrated in many o rgans including liver, lu ng an d intestines. Major concern has been a variety of neuropsychiatric reacti ons (disturbed sense of bala nce, ataxia, errors in operating machinery, strange dreams, anxiety, hallucinations, rarely convulsio ns) occurring in some recipients. For prophylaxis of malaria among travellers to areas with multidrug resistance; 250 mg (5 mg/kg in children) per week is started preferably 1- 2 weeks before travel to assess side effects in the individual. Quinine has no effect on preeryth rocytic stage and on hypnozoites of relapsing malaria, but kill s vivax, ovale and malariae gametes. Quinine has many other actions: Mepacrine (Quinacrine, Atabrine) It is an acridine derivative erythroc. It is obsolete as an antimalarial, but is also acti ve against giardia and tapeworms. Injections can cause pain and local necrosis in the muscle and thrombos is in the vein. Quinine is a weak analgesic and antipyretic; affects hearing and vision at higher doses. Cardiodepressant, antiarrhythmic and hypotensive actions are similar to quinidine (see C h. Quinine Quinine is the levo rotatory alkaloid obtained from cinchona bark, and the oldest antimalarial still in use. Its d-isomer quinidi nc is used as an antiarrhythm ic (and for malaria as well in some countries). However, resistance even to quinine has been described in certain parts of Southeast Asia and in Brazil where quinine + tetracycline has been the standard treatment of complicated malaria. Quinine-resistance has been encountered sporadically in India, particularly along Myanmar border. Though effective in terminating an acute attack of falciparum malaria, quinine may not prevent recrudescence-indicating incomplete clearance of the parasites. It is 70% bound to plasma proteins, especiall y a 1 acid glycoprotein, which increases during acute malarial in fection. Adverse effects Toxicity of quinine is high and dose related; 8- 10 g taken in a single dose may be fatal. Poisoning "ith still higher doses results in lhe above symptoms in an exaggerated form. Few individuals arc idiosyncra tic/ hypersensitive to quinine: cinchonism may appear after a single therapeutic dose. Q uinine occasionally causes hacmolysis, especially in pregnant women and m patients of falciparum malaria, resulting 111 haemoglobinuria (blac k \ ater fever) and kidney damage. During pregnancy it should be used only for serious falciparum ma laria, with special care to prevent hypoglycaemia. Proguanil (Chloroguanlde) It is a relatively slow-acting erythrocytic schizontocide for both Pf and P,i In addition. In the late 1940s and early 1950s proguanil was extensively used as a clinical curative for vivax malaria, especially in endemic areas with panially immune population. I lowcvcr, such use is now obsolete, because proguanil alone cannot be relied upon in nonimmunc patients, panicularly those with falciparnm malaria, due to slow response and chances of rapid resistance. Currently in India, proguan il has little role either in prophylaxis or in clinical cure of malaria. However, c linical trials have established that parenteral artemisinins are faster acting. Though, both components a re slow acting, the combination acts faster, so that it can be e mployed as a clinical curati ve for P falciparum. By the add ition of sulfo namide, development of resistance to pyrimetham ine is retarded. As clinical cu rati ve: S ulfadoxine 1500 mg + pyri methami ne 75 mg (3 ta b) single dose (children 9- 14 yr 2 tab, 5- 8 yr I½ tab, 1-4 yr I tab). T hey attain low blood concentrations, but are able to synergise with pyrimethami ne which also has long t½. The combination has the potential to cause serious adverse effects (cxfoliative dennatiti, Stevens-Johnson syndrome, etc. There is no evidence that single dose of the combination used for treating malaria harms the foetus during pregnancy, but should be given with folate supple mentation. Folate deficiency is rare; megaloblastic a nae mia and granul ocytopenia may occur with h igher doses, especially in those with marginal folate stores. Sulfonamide-pyrimethamine (S/P) Sulfonamides/ dapson e are not particularly efTective antimalarial drugs in thei r own right; have some inhibitory influence on the erythrocytic phase. In Ind ia, S/ P resistance a ppears to be sporadic, except in the orth east, particularly in areas bordering Myan mar from where 35-44% S/ P fa ilures were recorded. Pri maquinc d iffe rs from all other available antimalarials in having a marked effect on primary as we ll as secondary hepatic phases of the ma larial parasite. The mechanism of act ion of primaquine is not precisely known, but the reactive intermediate metabolites of primaquine are beleved to generate intraparasitic toxic oxidative species w hich disrupt the e lectron transport in plasmodial mitochondri a. Acquired resi stance to hypnozontocidal and gametocytocidal action of primaquine has not been ob erved. The most important tox ic poten tial is dose related haemolysis, methaemoglobinaem ia, tachypnoea and cyanosis. Pa sage of dark urine is an indication of haemo lysis, and primaquine should be promptly stopped if it occurs. Use Vivax malaria: the primary in dicat ion or primaqui ne is fo r radica l cure or re lapsi ng (vivax, ovale) malaria. It is oxidized in liver with a plasma t½ of 6- 8 hrs and excreted in urine withi n 24 hours. Doxycycline 200 mg/day has also been combined with artesunate 10 treat mcfloquine/chloroquine/S/P-resistant falciparum malaria in Thailand. Tafenoquine this new 8-aminoquinoline is being developed as a si ngle dose antirclapse drug fo r vivax malaria. The need fo r 14 daily doses o fprimaquine for effective re lapse prevention is the biggest hurdle in implementing antirelapse therapy. It markedly potentiates the antimalarial activity of quinine and artcmisinin, and is always used in combi nation with one of these. C lindamycin is a second choice drug to doxycycline for adding to quinine or 10 artesunate for the treatment of rnultidrug resistant falc iparum malaria. However, clindamycin is not used for prophylaxis of malaria, because of thrice daily dosing and ri,k of adverse cfl"ects. It is a sesquiterpene lactone endoperox ide acti ve against Pfalciparum resistant to a ll other antima la rial drugs as well as sensitive strains and other malaria l species. Howeve r, no c li nic a ll y use ful action is exerted on the preerythrocytic stage. By decreasi ng the population of ga metes, they reduce but do not totally interrupt disease transmission. Recnidescence depends upon the dose and duration of therapy as well as on severity of disease. Resistance among Pf to artemisinins is not a clinical problem yet, but in some areas (Cambodia, Thailand. After 5 days treatment recrudescence rate is ~ I0%, while with a 3 day course it is ~50%. After oral ingesti on, absorption is incomplete but fast, reaching peak in <60 min. The endoperoxide bridge in its molec ul e appea rs to interact wi th hae me in the parasite. Ferrous iron-mediated cleavage Arteether this compound developed in India is available for i. Because of its longer elimination t½ (23 hours), it is recommended in a 3 da y schedule, but is considered less dependable in severe/complicated malaria. Adverse effects Data from > I 0000 monitored patients shows that artesunate and artemether produce few adverse effects; most are mild: nausea, vomiting, abdominal pain, itching, drug fever, delayed haemolysis and other hypersensitivity reactions. Headache, tinnitus, dizziness, bleeding, dark urine, transient reticulopenia and leucopenia are rare and subside when the patient improves or the drug is stopped. Millions of patients have been treated so far without any serious neurological or other toxicity, but close monitoring of the patient is advocated. Interactions Concurrent administration of artemisinins with drugs prolonging Q-T, like antiarrhythmics, tricyclic antidepressants and phenothiazines may increase the risk of cardiac conduction defects. Even when used alone, they are almost 100% effective, but because of short duration of action recrudescence rates are high. In order to preserve their powerful antimalarial activity and to reduce recrudescence rates, they must be used in combin ation with a longacting schizontocide which acts by a different mechanism.

In 191 9 it "as established that rickets was due to deficiency of a dietary factor as well as lack of e:1 blood pressure chart urdu buy 240 mg calan free shipping. McCollum (1922) showed that th is fat soluble d ietary factor was different from vit A and its structure was determined in 1935 heart attack 5 hour energy cheap calan 80 mg mastercard. The interre lation between calciferol and cholecalcif"erol and their activation in the body has been fu lly understood only in the I 970s arrhythmia palpitations discount calan 120 mg buy on line. In ma n vit D 2 and D blood pressure cuff cvs 120 mg calan purchase amex, are equa lly active and calcitriol (active fom1 of D3) is mo re important physiologically; 25-0 H D hypertension in pregnancy discount 80 mg calan mastercard. The final I a -hydroxylation in kidney is rate lim iting and is controlled by many fac to rs. T hus, vie D should be considered a hormone because: (a) It is synthesized in the body (skin); under ideal conditions it is no t required in the diet. At least part of vit D action is quick (within minutes) by affecting calcium flux across intestinal mucosa! However, in hypervitaminosis D, influence of hypercalcaem ia overrides the direct action and more calci um is excre ted in urine. However, in contrast to os1eoporo is, the organic matrix (osteoid) is normal in these conditions. These are: hypercalcaemia, weakness, fatigue, vom iting, d iarrhoea, sluggishness, polyuria. Pharmacokinetics Vit D is well absorbed from the intestines in the presence of bile salts, mainly through lymphatics. Absorption of the 0 3 for m is somewhat better than that of Dr Malabsorption and steatorrhoea interfere with its absorption. Therefore, it docs not require hydroxylation at position I which is the limiting step in the generation of active form of vit D, and which takes place in the kidney. Alfacalc1 is orally active and clinically equally effective dol on long term basis to calcitriol. Its metabolic activation in liver does not pose a problem e, en in severe liver disease. Repeated serum calcium measurements are essential for regulation of maintenance dose. Hypercalcaemia s hould be watched for and therapy promptly interrupted for few days when it develops. Adm in istration of phosphate with high dose of calcitriol or alfacalc idol is beneficial. Senile or postmenopausal osteoporosis Age-re lated decrease in calciu m absorpt io n from g ut has been noted. Vit D 3 + calcium have been shown to improve calcium balance in osteoporotic fema les a nd e lde rly ma les. However, benefit in terms of improved bo ne mass or reduced fracture ris k is controversial or margina l (see p. Vit D defic ie ncy resu lts in secondary hyperparathyroid ism which contributes to osteoporos is. Calc itriol therapy carries the risk of hypercalcaemia, calcium stones and metastatic calcificatio n which should be watched for. Hypoparathyroidism D ihydrotachysterol or calcitri ol or alfaca lcidol are more effective tha n vit D2 or D3, because they act quickly and direc tly with ou t requiring h yd roxyl ation Use 1. Prophy laxis (oral or parenteral as appropriate) may be g iven in obstructi ve jaundice, steatorrhoea and other co nditions whi ch pred ispose to v it D deficiency. Metabolic rickets T hese are a group of conditions in whic h tissues do not respond to no rmal doses of vit D. Fanconi syndrome Vit D can raise the lowered phosphate leve ls that occur in this condition. Phenytoi n and pheno barbitone reduce the respons iveness of target tissues to calcitrio l; the ir pro longed use (for e pilepsy) can cause ric kets/osteomalacia. However, now it has been shown that plasma leve l of calcitri ol is normal, but its effect on intestine and bone is diminished. The fi rst gene ration compounds have simpler side c hains, are the least potent a nd seldom used now. The second and third generation compoun ds have an amin o or nitrogenous ring substitut ion in the side c hain, are more pote nt, ha ve hi ghe r effi cacy and additio na l mode of action. The two main components of bone are pro the in ma trix a nd the solid mineral phase (hydroxyapatite). On the surface of resorptive pi ts, the mine ral phase is solubilized in the clear acidic zone created at the ruffled border of osteoclasts, followed by resorption of protein matrix in this area by ac id hydro lases secreted from osteoclasts. Interference with mevalonate pathway may a lso impa rt a ntitumour activity on bony metastas is. A fter volume repletion, furose m ide is added to enhance Ca 2· exc re tion and to prevent vol ume overload. Osteolytic bone metastasis Pa rente ra l pamidronate/zo ledronate arrests osteolytic lesions and reduces bone pain. They have shown adjuvant value as add-on drugs in red uci ng breast carcinoma recurrences as we ll as in de laying skele tal events in women with bo ny metastasis. Th is also permits freque ncy of dosi ng to be reduced to as less as once a yea r, beca use a bout 50% of the absorbed/ injected drug is sequestrated in the bone. These measures are needed to prevent contac t of the drug with esophageal mucosa which results in esophagitis, erosions and ulcers. Oral b ioavai labil ity of I% a nd other fea tures a re si milar to a le ndronate. Dose: 5 mg daily or 35 mg/11eek or 150 mg once a monlh oral in the morning with a full glass of water. Adverse effects are thrombophlcbitis of injected vei n, bone pain, fever and leukopenia. Ad verse effec ts are esophagitis, gastri c erosion, retrosternal pain, flatu lence, headache, bodyache and initial fa ll in serum Ca 2+ level. Up to 50% of the drug entering the body is sequestrated in bone while the rest is excreted unchanged ma inly by the kidney. Osteoclastic acti vity is marked ly suppressed and an additional antitumour effect may be exerted by interference with mevalonate pathway. For hyperca lcaem ia, it is more effective, faster acting than pamidronate and therefore the drug of choice now. Another advantage is that it can be infused over 15 min (beca use of less venous irritation), whereas pamidronate needs 2-4 hours. It is now being used as a treatment option for osteoporo;is in both women and men, as well as to limit hony metastasis in breast and prostate cancers. The bone loss caused by gonadal suppressant therapy of these tumours is also counteracted. In osteoporo tic patients with high fract11rc risk, clcnosumab has been found to lower vertebral as well as hip fracture risk by 40-68%. In clinical trials it has been found to increase born: mineral dens ity and to decrease the risk of vertebra l as well as hip fracture. The neuromuscular blocking agents a rc used primarily in conjunction with genera l anaesthe tics to provide muscle re laxation for surgery, while centrally acting muscle relaxants are used mainly for painful muscle spasms and spastic neurological conditions. Tubocurarinc was first clinically used in I930s; many synthetic compounds including S11ccinylcholine w~re introduced subsequently. Search has continued for neuromuscular blockers to provide greater cardiovascular stability during surgery, and for drugs with difTering onset and duration of action lo suit specific requirements. Competitive block (Nondepolarizing block) T his is produced by c urare and re lated drugs. Injection of curare in the ventra l lymph sac caused inhibition of muscle twi tches but there was no effect if the blood supply of the hind limb was occluded. Soaking a portion of the scia tic nerve in curare solution did not affect the twitches and a curarized muscle still responded to direct stimulation- thus. The competitive blockers have affinity for the nicotinic (,f) cholinergic receptors at the muscle end pla te, but have no intrinsic activi ty. Competitive blockers generally have thick bulky molecules a nd were term ed Pachycurare by Bovet (195 1). The competiti ve blockers a lso block prejunctional nico tinic receptors located on moto r nerve endings. Because in the foca lly innervated mammalian musc le, stimulati on is trans ient; longer lasting depolarization of muscle end plate produces repetitive excitation of the fibre. In the multipl ely innervated contracture muscle (rectus abdomi nis of frog) sti mulation is prolonged resulting in susta ined contraction. They induce prolonged partial depolarization of the region around muscle end plate resulting in inactivation of Na· channe ls (because transme mbrane potential d rops to about -50 mV). In other words, a zone of inexcitability, is created around the end plate preventing activation of the muscle fibre. In man and fast contracting muscle (tibialis ante ri or) of cat, normally only phase I block occurs. The rate of attainment of peak effect and the duration for which it is maintained depends on the drug (Table 25. In general, the more potent nondepolarizing blockers have a longer onset of act ion. Depolarizing blockers typically produce fasciculations lasting a few seconds before inducing flaccid paralysis, but fascic ulations are not promi nent in we ll-anaesthetized patients. Apnoea generally occurs within 45- 90 sec, but lasts onl y 2- 5 min; recovery is rapid. Clinical monitoring of neuromuscular block In anaesthetic practice neurom uscular block (especially during recovery) is monitored by recording contractile responses of thumb muscles to transeutaneous ulnar nerve 1. Skeletal muscles Intravenous injection of nondepolarizing blockers rapidly produces muscle weakness followed by flaccid paralysis. S ince single t\ itch response have to be interpreted in comparison to twitches before the blocker. Reappearance of 2nd t, itch (T,) corresponds to - I 0% recovery (- 90% residual block) and that of 4th twitch (T4) to - 25% recovery. Many anaesthesiologists prefer to use the lc:ss painful, ariant of tetanic stimulation. The s trength of response during the 2nd burst relative to the first is a measure of the recovery from block. This does not involve immune system and is due to the bulky cationic nature of the molecule. Flushing, bronchospasm and increased respiratory secretions are the other efTccts. In patients anaesthetised with ether/halothane/ isoflurane, the dose may be 1/ 3- 1/ 2 01 the figure given. This is due to(a) gang lionic blockade (b) hista mine release and (c) reduced venous return- a result of paralysis of limb and respiratory muscles. Efflux of inlrncellular K occurs in these conditi ons which is augmented by prolonged depolarizat ion of skeletal muscles. The ganglion blocking act ivi ty of competitive blockers may enhance postoperative paralytic ileus after abdominal operations. All neuromuscular blockers are quaternary compound - do not cross blood-brain barrier. Because of longer d uration of ac tion, needing reversal, its use is now restricted to prolonged operations, especially neurosurgery. Doxacurium A bisquatemary mu clc relaxant having the least rapid onset and the longest ac tion. It induces rapid, complete and pred ictab le paralysis wi th spo ntaneo us recovery in ~5 min. Pipecuronium Another steroidal muscle re laxant with a slo w onset and long duration of action: whi ch is recommended for prolonged surgeries. It exerts li ttle cardiovascular action, though trans ient hypo tension and bradycardia can occu r. A close congener of pancuronium with a shorter duration of action due to rapid d istribution and conside rable hepati c me tabolis m. It is excre ted mainly in bi le, recovery is generally s po ntaneous, but may need neostigm ine reversal. Cardiovascular stab ii ity is still better due to mild hista min e releasing and ganglion ic action; tachycardi a sometimes occurs. Atracurium A bisquatem ary competitive blocker, 4 times less potent than panc uronium and shorter acting, so that reversal is mostly not required. The unique feature of atracurium is inactivation in plasma by spontaneous nonenzymatic degradation (Hofmann e limination) in addition to that by cholinesterases. Consequently its duration of action is not a ltered in patients with hepatic/rena l insuffic iency or hypodynamic circulation. Avail ability of less toxic cisatracurium has sent racemic atracurium in the background. Dose and speed of injection related transient cutaneous fl ushing can occur due to histamine release. General anaesthetics po tentiate compe titi ve blockers; ether in particular, fol lowed by fluorinated hydrocarbons of w hi ch isoflurane is most potentiating and halothane the least. Though neostigmine also reverses gang lion ic blockade to some extent, hypotension and bronchospasm can occur due to muscarinic action or neostigmine; this can be prevented by prior atropinization (atropine or glycopyrrolate 5- 10 µ g/kg i. Pretreatme nt with ll 1 antihista mines reduces hypote nsion due to histami ne re leasing neuromuscular blockers. Most importantly, it does not provoke histamine re lease and side effects are fewer. Currently, cisatracurium is one of the preferred muscle re laxants, especially for li ver/kidney disease patients and for the e lderl y. The same drug also serves as maintenance muscle re laxant, seldom needing reversal.

Purchase calan 120 mg line. How to use (Dr Morepen BP 09) Digital Blood Pressure Monitor.

Syndromes

• Feeling alone
• Food allergies
• A yellowing of the whites of the eyes (icterus)
• Degenerative nerve illness
• Use a vaporizer to add moisture to the air you breathe.
• Hips
• Muscle weakness or loss of movement in a group of muscles (paralysis)
• GHRH or GHRH-arginine stimulation (to help diagnose a lack of growth hormone)
• Thirst

Side efTects a re mainly gastrointestinal disturbances blood pressure 70 over 30 buy calan 240 mg visa, bradycardia arrhythmia yawning order cheap calan, weakness prehypertension for years buy discount calan 120 mg line, cough and dermatological reactions prehypertension warsaw 2014 discount calan master card. A recent meta-analysis has also noted unfavourable cardiovascular and mortality outcomes with clronedaronc arteria hyaloidea calan 120 mg order online. Sotalol is not a Na~ cha nnel blocker-does not depress conductio n in fast response tissue. Verapamil or the many Ca2- channel blockers, verapamil has the most prominent cardiac electro physiological actio n (Table 39. Its antiarrhythmic aspects are described here, while other aspects are covered in Ch. Reflex sympathetic stimulation due to vasod ilata tion partly counteracts the direct bradycardia producing action. As a result A-V conduct io n is markedly s lowed (P-R interval inc reases) and reentry involving A-V node is terminated. Verapamil has negative inotropic action due to interference with Ca 2+ medi ated excitation-contraction coupling in myocardium. In contrast to f3 blockers, verapami l prophylaxis does not reduce mortality in post-M l patients. It is also not recommended for digita lis toxicity, because additive A-V block may occur. In case of inadequate response, Diltiazem the direct cardiac actions of diltiazem are similar to those of verapamil. Bronchospasm may be precipitated in asthmatics; verapamil is the drug of choice for s uch patients. Drugs for sinus tachycardia lvabradine Inappropriate s inus tachycardia is a relatively uncommon disorder which may produce troublesome symptoms like palpation, dyspnoea. Almost complete e limination occurs in a sing le passage throug h coronary circulation. Choice and use of antiarrhythmic drugs Mere detection of an arrhythmia does no t necessitate treatment. The proarrhythmic potential of antiarrhythmi c drugs and the increased risk of sudden cardiac death seems to olTset any survival advantage that these drugs might affo rd over long-term. Only propranolol and to some extent amiodaronc have been shown to reduce cardiovascular mortality in the longterm. On the other hand, vigoro us therapy is indicated when: · Arrhythmia is life-threateni ng. In the abo ve situations an tiarrhythmic drugs are mostly needed for short periods. The aim is to improve cardiovascular function either by restoring sinus rhythm, or by controlling ventricular rate, or by conversion to a more de irable pattern of electrical and mechanical acti vity. Despite extensive investigation, choice of an antiarrhythmic is still largely emp irical. A practical guide to the choice and use of antiarrhythmic drugs is summarized in the box on next page. Lidocaine / procainamide / amiodarone Cardioversion (if haemodynamically unstable) 6. The underlying pathology is- severe arteri osclerotic affliction of larger coro nary arteries (conducting vessels) wh ich run epicardia lly and send perforating branches to supply the deeper tissue (F ig. They may also cause favo urable red istribution of blood flow to the ischaemic areas. Abno rmally reactive a nd hypertrophied segments in the coronary arteri es have been demonstrated. Other organic nitrates were added later, but a breakthrough was achieved in 1963 when propranolol was used for chronic prophylaxis. A number of vasodilator and other d111gs have been promoted from time to time, but none is unifonnly effective. In fact, nitrates do not appreciably increase total coronary flow in angina patients. Preload reduction Nitrates dilate veins more than arteries · peripheral pooling of blood · decreased venous return, i. Reduction in ventricular radius decreases the tension that must be generated in the ventricular wall- hence decreased 0 2 consumption. The decrease in end diastolic pressure abolishes the s ubendocardial crunch by restoring the pressure gradient across ventricular wall due to which subendocardial perfusion occurs during diastole. It is through their action on peripheral veins that nitrates exert major beneficial effects in classical angi na. This action contributes to the reduction in cardiac work which is directly proportional to aortic impedance. With usual doses, and if the patient does not stand still (which favours pooling of b lood in the legs), tachycard ia is not prominent. Afterload reduction Mechanism of relief of angina the relaxant effect on larger coronary vessels is the principal action of nitrates benefiting variant angina by counteracting coronary spasm. In classical angina undoubtedly the primary effect is to reduce cardiac work by action on peripheral vasculature, though increased blood supply to ischaemic area may contribute. Exercise tolerance of angi na patients is improved because the same amo unt of exercise causes lesser augmentation of cardiac work. Heart and peripheral blood flow Nitrates have no direct stimulant or depressant action on the heart. They dilate cuta neous vesse ls (especially over face and neck responsible for flushing) and meningeal vessels causi ng headache. Splanchnic and renal blood flow decreases to compensate for vasodilatation in other areas. It has been; ugge;ted that preferential dilatation of cpicardial conductmg ancnes over autorcgulatory ancriolcs is also due to diflerential distribution of nitrate metabolizing en,:yme, in these, essds. Though nitrates have been traditionally classified into shortacting and long-acting. Organic nitrates are lipid-soluble: well absorbed from buccal mucosa, intestines and skin. Ingested orall y, all except isosorbide mononitrate undergo extensive and variab le first pass metabolism in liver. They are rapidly denitrated by a gluta thione reductase and a mitochondrial aldehyde dchydrogcnase. The partly denitrated metabolites are less Pharmacokinetics Adverse effects these are mostly due to vasodi latation. Rashes are rare, though relatively more common with pentaerythri tol tetran itrate. Th is tolerance weans o rf rapidly (withi n hours) when th e body is free of the drug. The most practical way to prevent nitrate tolerance is to provide nitrate free intervals everyday. Sudden wi thdrawal af1er prolonged exposure has resulted in spasm of coronary and peripheral blood vessels. Angina threshold is lowered during the ni trate free interval in some patients: episodes of angina may increase. The tablets mu st be sto re d in a tightly closed glass (not p lastic) container lest the drug should evaporate away. The subli ngual route is used when terminating an attack or aborting an imminent o ne is the aim. It acts within 1- 2 min (peak blood level in 3-i min) because of direct absorption into systemic c irculation (bypassing li ver where almost 90% is metabolized). Plas ma t ½ is 2 min, duration of action de pends on the pe riod it re mains availab le for absorption from bucca l mucosa. A s ublingua l spray fo rmulati on has been recently marketed- acts more rapidly and is more stable than sublingual tablet. Hepatic metabolizing capacity can be overwhe lmed by administering a large dose (5- 15 mg) orall y. A transderma l patch has been developed which provides steady de li very for 24 hours. A transmucosal dosage form w hich has to be stuck to the gums under the upper lip has also been produced. The t½ is 40 min, but sustained release formulation may afford protection for 6- 10 ho urs. Erythrityl tetranitrate and pentaerythritol tetranitrate these are longer-acting nitrates used only for c hroni c prophy lax is. Sustained release oral prepa rations a re now available for 2- 3 times a day dosing. There has been considerable scepticism in the past about the efficacy of orally administered long-acting nitrates. Studies with high doses have shown that fi rstpass metabolism in liver can be saturated and haemodynamic effects lasting 4-6 hours do occur. Angina pectoris Nitrates a re effect ive in classical as well as varian t ang ina. When administered orally it undergoes little first pass metabolism: bioa vailability is high, interindividual differences are minima l and it is longer acti ng (t½ 4- 6 hr). However, evide nce tha t it d ecreases mo rtality is no t rob ust; prognostic benefits appear marg ina l. Nitrates taken before a meal facilita the feeding in esophageal acha lasia by reducing esophageal tone. M oreover, chronic nitrate therapy in a ng ina does no t decrease cardiac mortality. Ni trates are useful by decreas ing pre load (myocardial work) as well as by increasing coronaty flow (dilatation and antagonism of coronary spasm, if present). The f:3 blockers are indicated in al l patients (if there are no contraindications) to reduce myocardial oxygen de mand. Revascularization by thrombolytics/coronary angioplasty with stents/ coronary bypass surge ry is considered in high ri sk patients. The latter are particularl y prone to worsen vari ant a ngina due to unopposed a receptor mediated coronary constriction that ma y accentuate the coronary s pas m. As per current g uidel ines, they s houl d be the fi rst line drugs in all s table angina patients, unless contraindicated. However, flow to the ischaemic subendocardial region is not reduced because of favo urable redistribution and decrease in ventric ular wall tension. While these effects are marg ina l at rest, blockers limit the increase in cardiac work that occurs d uring exercise or anxiety by thei r antiadrenergic action on heart. Redu ction in heart rate indi rectly improves coronary perfosion by prolong ing diasto le during wh ich subendocardial perfus ion occurs. It had additional cardiodeprcssant property, but its mechanism of action was not known. Fleckenstein (1967) showed that it interfered with Ca 1 · movement into the cell. Blocker w-Conotoxin (a) Voltage sensitive channel Activated when membrane potential drops to around -40 m V or lower. They are composed of a major ex, subunit which encloses the ion channel and other modulatory subunits like cx,P, y and 6. La L-type Ca1 · channels each subunit exists in multiple isoforms which may be site specific. Moreover, distribution may be heterogeneous in different parts of the vascular bed. Further, different drugs may have differing affinities for various site specific isoforms of the L-channcls. Activated - -Ill Ca2· / Delayed by Verapamil, Diltiazem Inactivated channel Smooth muscle Smooth muscles depolarize primarily by inward Ca2· movement through voltage sensitive L-type c han ne l. Extravascular smooth muscle (bronc hi al, biliary, intestinal, vesical, ute rine) is also relaxed. These additional mechanisms may account for their predominant smooth muscle relaxant action. Automaticity and conductivity of these cells appear to be dependent on the rate of recovery of the Ca2channel. Moreover, channel blockade by verapamil is enhanced at hi gher rates of stimulation, that by nifedipine is independent of freq uency, while diltiazem is intermediate. Effect of di ltiazem on sinus node automaticity and A-Y conduction is similar to that of verapamil. The relative potencies to block slow channels in smooth muscle do not parallel those in the heart. Channel blocking potency Frequency dependence of channel blockade Channel recovery rate Cardiac effects (In vivo at usual clinical doses) Heart rate A-Vconduction velocity Contractility Output Vascular smooth muscle relaxation Clinical use in ++ ++ +++ + + Much delayed No effect Delayed J. Verapamil It dilates arterioles and has some a adrenergic blocking activity, thereby decreases t. The pronounced direct cardiodepressant effect is partia ll y offset in vivo by renex effects of peripheral vasodilatation. Interactions Verapamil should not be given with 13 blockers- add itive sinus depression, conduction defects or asystole may occur. It increases plasma digoxin level by decreasing its excretion: toxicity can develop. It should not be used along wi th other cardiac depressants li ke quinidine and disopyramide.

References

• Lau LC, Adaikan PG: Possibility of inhibition of calcium-activated chloride channel rescuing erectile failures in diabetes, Int J Impot Res 26(4):151n155, 2014.
• Grewal SS, Hunt JP, O'Connor SC, Gianturco LE, Richardson MW, Lehmann LE. Helicobacter pylori associated gastric Burkitt lymphoma. Pediatr Blood Cancer 2008;50:888.
• Phepls DL. Retinopathy of prematurity. Pediatric Clin. Am 1993;40:705.
• Voepel-Lewis T, Malviya S, Tait AR: A prospective cohort study of emergence agitation in the pediatric postanesthesia care unit, Anesth Analg 96:1625- 1630, 2003.
• Fayed AM, White CJ, Ramee SR, et al. Carotid and cerebral angiography performed by cardiologists: cerebrovascular complications. Catheter Cardiovasc Interv. 2002;55:277-280.
• Fredericks CM, Anderson GF, Pierce JM: Electrical and mechanical responses of intact canine ureter to elevated intravesical pressure, Invest Urol 9:496, 1972.
• Sobrier ML, Attie-Bitach T, Netchine I, et al: Pathophysiology of syndromic combined pituitary hormone deficiency due to a LHX3 defect in light of LHX3 and LHX4 expression during early human development, Gene Expr Patterns 5:279n284, 2004.